DOCSLIB.ORG

LSD – Unterstützte Psychotherapie Bei Personen Mit Angstsymptomatik in Verbindung Mit Fortgeschrittenen Lebensbedrohenden Erkrankungen

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
LSD – Unterstützte Psychotherapie Bei Personen Mit Angstsymptomatik in Verbindung Mit Fortgeschrittenen Lebensbedrohenden Erkrankungen Clinical Study Protocol LSD – unterstützte Psychotherapie bei Personen mit Angstsymptomatik in Verbindung mit fortgeschrittenen lebensbedrohenden Erkrankungen. Eine doppelblinde, plazebokontrollierte Phase-II Dosis-Wirkungs- Pilotstudie LSD – assisted psychotherapy in persons suffering from anxiety associated with advanced-stage life threatening diseases. A phase-II, double-blind, placebo-controlled dose-response pilot study Original Protocol Version Date: January 9, 2007 SPONSOR MAPS PRINCIPAL INVESTIGATOR: Dr. med. Peter Gasser; [email protected] Facharzt FMH Psychiatrie + Psychotherapie Hauptbahnhofstrasse 5 4500 Solothurn / Switzerland MEDICAL MONITOR Rick Doblin, PhD; [email protected] ; Office: (1) 617-484-8711 STUDY MONITOR Valerie Mojeiko; [email protected] ; Office (1) 831-336-4325 Mobile (1) 941-726-3672 Fax (1) 831-336-3665 For trial related emergencies out of office hours please contact 617-276-7806 Property of MAPS MAPS Clinical Study Protocol L-DA1 09 Jan. 07 Page 1 of 64 Table of Contents German Summary ...........................................................................................................3 Hintergrund ....................................................................................................................3 Ziel ...................................................................................................................................4 Methode ..........................................................................................................................4 Erwarteter Nutzen des vorliegenden Projektes ..........................................................5 Ethics ..................................................................................................................................6 Informed Consent of Subject ........................................................................................6 Introductory Statement ..................................................................................................7 Study Design ..................................................................................................................9 Objectives: ....................................................................................................................10 Background and Significance ....................................................................................10 General Investigational Plan ......................................................................................12 Investigators .................................................................................................................12 Subjects .........................................................................................................................12 Inclusion Criteria .........................................................................................................13 Exclusion Criteria ........................................................................................................14 Prescreening and Informed Consent .........................................................................14 Subject Numbering ......................................................................................................15 Randomization .............................................................................................................16 Removal of Subjects from Therapy or Assessment ................................................16 Psychotherapy ..............................................................................................................16 Psychotherapy During Experimental Session............................................................17 Open Label Continuation for Active Placebo Patients ..............................................18 Data Analysis ...............................................................................................................19 Drugs and Dosage ........................................................................................................20 Methods ........................................................................................................................20 Assessment / Measures ..............................................................................................23 Monitoring for Risks ....................................................................................................26 Acute Psychological Distress .....................................................................................26 Medical Emergencies ..................................................................................................27 Adverse Events ............................................................................................................28 Serious Adverse Events ..............................................................................................29 Adverse Event Collection ...........................................................................................30 Collection of Concomitant Medications ...................................................................30 Laboratory Assessments .............................................................................................30 Study Monitoring, Auditing and Documentation ....................................................30 Risks to Participants ....................................................................................................31 MAPS Clinical Study Protocol L-DA1 09 Jan. 07 Page 2 of 64 Risks and Discomforts Related to Screening and Baseline Examination..................31 Risks and Discomforts of Psychotherapy ..................................................................31 Risk of the Experimental Drug (LSD).......................................................................31 Panic attacks, severe generalized anxiety, or persisting insomnia.............................32 Self-injurious behavior...............................................................................................32 Psychosis, suicidal thoughts or impulses...................................................................32 Chronic neuropsychological effects...........................................................................33 Reproductive and Developmental Risks....................................................................34 Abuse Liability...........................................................................................................34 Risks of Active Placebo dose of LSD........................................................................35 Alternative Treatment and Procedures ....................................................................35 Risk-Benefits Analysis ................................................................................................35 Confidentiality ...............................................................................................................36 Costs to Participants .....................................................................................................37 Patient’s Rights / Insurance ........................................................................................37 Record Retention ...........................................................................................................37 Chemistry, Manufacturing and Control Information ...........................................38 Pharmacokinetics and Pharmacodynamics .............................................................39 Primary Pharmacodynamics .......................................................................................41 Drug Activity Related to Proposed Action ................................................................41 Safety Pharmacology ..................................................................................................42 Abuse Liability...........................................................................................................44 Pharmacokinetics/Toxicokinetics ..............................................................................45 Absorption, Distribution, Metabolism, Excretion......................................................45 Toxicology ....................................................................................................................47 Acute toxicity.............................................................................................................47 Reproductive Toxicity ...............................................................................................47 Previous Human Experience ......................................................................................48 References .......................................................................................................................49 Signature Page: ..............................................................................................................59 Appendix A: Investigators ..........................................................................................60 Appendix B: Daily Diary - example .........................................................................62 Appendix C: Letter for Recruitment of Participants ............................................63 MAPS Clinical Study Protocol L-DA1 09 Jan. 07 Page 3 of 64 German Summary Hintergrund Nachdem LSD im Jahre 1943 durch den Schweizer Chemiker Albert Hofmann in Basel entdeckt wurde, erfolgte eine fast dreissig Jahre dauernde rege Forschungstätigkeit, die im psychiatrischen
Load more

Recommended publications
  • Cathinone-Derived Psychostimulants Steven J
    Review Cite This: ACS Chem. Neurosci. XXXX, XXX, XXX−XXX pubs.acs.org/chemneuro DARK Classics in Chemical Neuroscience: Cathinone-Derived Psychostimulants Steven J. Simmons,*,† Jonna M. Leyrer-Jackson,‡ Chicora F. Oliver,† Callum Hicks,† John W. Muschamp,† Scott M. Rawls,† and M. Foster Olive‡ † Center for Substance Abuse Research (CSAR), Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania 19140, United States ‡ Department of Psychology, Arizona State University, Tempe, Arizona 85281, United States ABSTRACT: Cathinone is a plant alkaloid found in khat leaves of perennial shrubs grown in East Africa. Similar to cocaine, cathinone elicits psychostimulant effects which are in part attributed to its amphetamine-like structure. Around 2010, home laboratories began altering the parent structure of cathinone to synthesize derivatives with mechanisms of action, potencies, and pharmacokinetics permitting high abuse potential and toxicity. These “synthetic cathinones” include 4-methylmethcathinone (mephedrone), 3,4-methylenedioxypyrovalerone (MDPV), and the empathogenic agent 3,4-methylenedioxymethcathinone (methylone) which collectively gained international popularity following aggressive online marketing as well as availability in various retail outlets. Case reports made clear the health risks associated with these agents and, in 2012, the Drug Enforcement Agency of the United States placed a series of synthetic cathinones on Schedule I under emergency order. Mechanistically, cathinone and synthetic derivatives work by augmenting monoamine transmission through release facilitation and/or presynaptic transport inhibition. Animal studies confirm the rewarding and reinforcing properties of synthetic cathinones by utilizing self-administration, place conditioning, and intracranial self-stimulation assays and additionally show persistent neuropathological features which demonstrate a clear need to better understand this class of drugs.
    [Show full text]
  • Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
    Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209
    [Show full text]
  • Anxiolytic-Like Activity of SB-205384 in the Elevated Plus Maze Test in Mice
    Psicothema 2006. Vol. 18, nº 1, pp. 100-104 ISSN 0214 - 9915 CODEN PSOTEG www.psicothema.com Copyright © 2006 Psicothema Anxiolytic-like activity of SB-205384 in the elevated plus maze test in mice José Francisco Navarro, Estrella Burón and Mercedes Martín-López Universidad de Málaga Recent studies point to a major role for α2-containing GABA-A receptors in modulating anxiety. Ho- wever, the possible implication of GABA-A receptors containing the α3 subunit on anxiety is less known. The aim of this study was to examine the effects of SB-205384 (0.5-4 mg/kg, ip), an α3 su- bunit positive modulator of GABA-A receptor, on anxiety tested in the elevated plus-maze in male mi- ce, using classical and ethological parameters. Mice treated with SB-205384 showed an increase in the frequency of entries and the time spent in open arms, as well as a reduction in the time spent in closed arms, as compared with the control group. A notable increase of «head-dipping» unprotected and a re- duction of «stretched-attend posture» protected was also evident. These findings indicate that SB- 205384 exhibits an anxiolytic-like profile in the elevated plus-maze test, suggesting that GABA-A re- ceptors which contain the α3 subunit might be involved in regulation anxiety. Actividad ansiolítica del SB-205384 en el laberinto elevado en cruz en ratones. Recientes investiga- ciones indican que los receptores GABA-A que contienen subunidades α2 desempeñan un importan- te papel en la modulación de la ansiedad. Sin embargo, la posible implicación de los receptores GA- BA-A que contienen la subunidad α3 es menos conocida.
    [Show full text]
  • University of Dundee Decreased Mental Time Travel to the Past
    University of Dundee Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide Speth, Jana; Speth, Clemens; Kaelen, Mendel; Schloerscheidt, Astrid M.; Feilding, Amanda; Nutt, David J. Published in: Journal of Psychopharmacology DOI: 10.1177/0269881116628430 Publication date: 2016 Document Version Peer reviewed version Link to publication in Discovery Research Portal Citation for published version (APA): Speth, J., Speth, C., Kaelen, M., Schloerscheidt, A. M., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2016). Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide. Journal of Psychopharmacology, 30(4), 344-353. https://doi.org/10.1177/0269881116628430 General rights Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain. • You may freely distribute the URL identifying the publication in the public portal. Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove
    [Show full text]
  • Natural Psychoplastogens As Antidepressant Agents
    molecules Review Natural Psychoplastogens As Antidepressant Agents Jakub Benko 1,2,* and Stanislava Vranková 1 1 Center of Experimental Medicine, Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, 841 04 Bratislava, Slovakia; [email protected] 2 Faculty of Medicine, Comenius University, 813 72 Bratislava, Slovakia * Correspondence: [email protected]; Tel.: +421-948-437-895 Academic Editor: Olga Pecháˇnová Received: 31 December 2019; Accepted: 2 March 2020; Published: 5 March 2020 Abstract: Increasing prevalence and burden of major depressive disorder presents an unavoidable problem for psychiatry. Existing antidepressants exert their effect only after several weeks of continuous treatment. In addition, their serious side effects and ineffectiveness in one-third of patients call for urgent action. Recent advances have given rise to the concept of psychoplastogens. These compounds are capable of fast structural and functional rearrangement of neural networks by targeting mechanisms previously implicated in the development of depression. Furthermore, evidence shows that they exert a potent acute and long-term positive effects, reaching beyond the treatment of psychiatric diseases. Several of them are naturally occurring compounds, such as psilocybin, N,N-dimethyltryptamine, and 7,8-dihydroxyflavone. Their pharmacology and effects in animal and human studies were discussed in this article. Keywords: depression; antidepressants; psychoplastogens; psychedelics; flavonoids 1. Introduction 1.1. Depression Depression is the most common and debilitating mental disease. Its prevalence and burden have been steadily rising in the past decades. For example, in 1990, the World Health Organization (WHO) projected that depression would increase from 4th to 2nd most frequent cause of world-wide disability by 2020 [1].
    [Show full text]
  • Anxiety-Inducing Dietary Supplements: a Review of Herbs and Other Supplements with Anxiogenic Properties
    Pharmacology & Pharmacy, 2014, 5, 966-981 Published Online September 2014 in SciRes. http://www.scirp.org/journal/pp http://dx.doi.org/10.4236/pp.2014.510109 Anxiety-Inducing Dietary Supplements: A Review of Herbs and Other Supplements with Anxiogenic Properties Caitlin E. McCarthy, Danielle M. Candelario, Mei T. Liu Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, USA Email: [email protected] Received 10 August 2014; revised 11 September 2014; accepted 20 September 2014 Copyright © 2014 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract Anxiety disorders comprise the most common group of mental disorders to affect the general population in the United States. These disorders are heterogeneous in nature, highly comorbid with one another, and pose a degree of difficulty regarding diagnosis and management. The exact etiology and pathophysiology of anxiety remains to be elucidated; however, it is likely that it is multifactorial, and all potential causes of anxiety must be investigated, including substance-in- duced anxiety. Among substances that may induce anxiety are dietary supplements. As utilization of these products appears to be high in the US population, it is important to identify which of available supplements may cause anxiety. Objective: To review the scientific literature to identify dietary supplements associated with induction of anxiety and related symptoms. Methods: A search of Natural Medicines Comprehensive Database, MedlinePlus Herbs and Supplements, and Natural Standard was performed to identify dietary supplements with anxiogenic properties.
    [Show full text]
  • Deficient Cognitive Performance in Aged Rats Depends on Low Pregnenolone Sulfate Levels in the Hippocampus
    Proc. Natl. Acad. Sci. USA Vol. 94, pp. 14865–14870, December 1997 Neurobiology Neurosteroids: Deficient cognitive performance in aged rats depends on low pregnenolone sulfate levels in the hippocampus MONIQUE VALLE´E*†,WILLY MAYO*†‡,MURIEL DARNAUDE´RY*, COLETTE CORPE´CHOT§,JACQUES YOUNG§, MURIEL KOEHL*, MICHEL LE MOAL*, ETIENNE-EMILE BAULIEU§,PAUL ROBEL§, AND HERVE´ SIMON* *Laboratoire de Psychobiologie des Comportements Adaptatifs, Institut National de la Sante´de la Recherche Me´dicale,Unite´259, rue Camille Saint Sae¨ns, 33077 Bordeaux cedex, France; and §Laboratoire des Communications Hormonales, Institut National de la Sante´de la Recherche Me´dicale,Unite´33, 80 rue du Ge´ne´ralLeclerc, 94276 Le Kremlin Biceˆtrecedex, France Contributed by Etienne-Emile Baulieu, September 29, 1997 ABSTRACT Pregnenolone sulfate (PREG S) is synthe- these studies, the animal, usually a rat or a mouse, must avoid sized in the nervous system and is a major neurosteroid in the electrical footshocks (active or passive avoidance), or search rat brain. Its concentrations were measured in the hippocam- for a food reward after food deprivation. The suitability of pus and other brain areas of single adult and aged (22–24 these procedures for evaluating specific memory performance month-old) male Sprague–Dawley rats. Significantly lower has been questioned (12), since they may induce alterations of levels were found in aged rats, although the values were widely the motivational or emotional status of the animals. Moreover, scattered and reached, in about half the animals, the same the effects of the administration of steroids on their cerebral range as those of young ones. The spatial memory perfor- concentrations have seldom been evaluated (8, 13).
    [Show full text]
  • The Gerbil Elevated Plus-Maze I: Behavioral Characterization and Pharmacological Validation Geoffrey B
    The Gerbil Elevated Plus-Maze I: Behavioral Characterization and Pharmacological Validation Geoffrey B. Varty, Ph.D., Cynthia A. Morgan, B.Sc., Mary E. Cohen-Williams, B.Sc., Vicki L. Coffin, Ph.D., and Galen J. Carey, Ph.D. Several neurokinin NK1 receptor antagonists currently produced anxiolytic-like effects on risk-assessment being developed for anxiety and depression have reduced behaviors (reduced stretch-attend postures and increased affinity for the rat and mouse NK1 receptor compared with head dips). Of particular interest, the antidepressant drugs human. Consequently, it has proven difficult to test these imipramine (1–30 mg/kg p.o.), fluoxetine (1–30 mg/kg, p.o.) agents in traditional rat and mouse models of anxiety and and paroxetine (0.3–10 mg/kg p.o.) each produced some depression. This issue has been overcome, in part, by using acute anxiolytic-like activity, without affecting locomotor non-traditional lab species such as the guinea pig and activity. The antipsychotic, haloperidol, and the gerbil, which have NK1 receptors closer in homology to psychostimulant, amphetamine, did not produce any human NK1 receptors. However, there are very few reports anxiolytic-like effects (1–10 mg/kg s.c). The anxiogenic describing the behavior of gerbils in traditional models of ␤-carboline, FG-7142, reduced time spent in the open arm anxiety. The aim of the present study was to determine if the and head dips, and increased stretch-attend postures (1–30 elevated plus-maze, a commonly used anxiety model, could mg/kg, i.p.). These studies have demonstrated that gerbils be adapted for the gerbil.
    [Show full text]
  • Effect of Chronic DL-Amphetamine Exposure on Brain Volume, Anxiogenic, Locomotor, and Social Behaviors in Male SD Rats
    Journal of Behavioral and Brain Science, 2014, 4, 375-383 Published Online August 2014 in SciRes. http://www.scirp.org/journal/jbbs http://dx.doi.org/10.4236/jbbs.2014.48036 Effect of Chronic DL-Amphetamine Exposure on Brain Volume, Anxiogenic, Locomotor, and Social Behaviors in Male SD Rats Alison F. Kafka, Daniel A. Heinz, Timothy M. Flemming, Paul J. Currie* Department of Psychology, Reed College, Portland, USA Email: *[email protected] Received 9 June 2014; revised 24 July 2014; accepted 5 August 2014 Copyright © 2014 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract Research examining the long-term effects of drugs such as Adderall™, a mixed DL-amphetamine, as a first-line treatment strategy for those diagnosed with attention deficit hyperactivity disorder (ADHD), is very much lacking. In order to address this, the present study sought to examine possi- ble behavioral and neuroanatomical effects of chronic oral exposure to DL-amphetamine admi- nistered at a relatively low dose to the developing male Sprague Dawley rat. Animals were admi- nistered a mixture of chocolate drink and DL-amphetamine at a dose of 1.6 mg/kg for 36 days, be- ginning at PD 24 and ending at PD 60. Anxiety, a potential side effect of stimulant treatment, was assessed using three paradigms: The open field test (OF), the social interaction test (SI), and the elevated plus maze (EPM). The OF and SI were conducted using repeated testing over the course of five weeks.
    [Show full text]
  • Elevated Mazes As Animal Models of Anxiety: Effects of Serotonergic Agents
    Anais da Academia Brasileira de Ciências (2007) 79(1): 71-85 (Annals of the Brazilian Academy of Sciences) ISSN 0001-3765 www.scielo.br/aabc Elevated mazes as animal models of anxiety: effects of serotonergic agents SIMONE H. PINHEIRO1, HÉLIO ZANGROSSI-Jr.2, CRISTINA M. DEL-BEN1 and FREDERICO G. GRAEFF1 1Departamento de Neurologia, Psiquiatria e Psicologia Médica, Hospital das Clínicas Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo Avenida Bandeirantes 3.900, 14048-900 Ribeirão Preto, SP, Brasil 2Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo Avenida Bandeirantes 3.900, 14049-900 Ribeirão Preto, SP, Brasil Manuscript received on March 23, 2006; accepted for publication on April 12, 2006; contributed by FREDERICO G. GRAEFF* ABSTRACT This article reviews reported results about the effects of drugs that act upon the serotonergic neurotransmission mea- sured in three elevated mazes that are animal models of anxiety. A bibliographic search has been performed in MED- LINE using different combinations of the key words X-maze, plus-maze, T-maze, serotonin and 5-HT, present in the title and/or the abstract, with no time limit. From the obtained abstracts, several publications were excluded on the basis of the following criteria: review articles that did not report original results, species other than the rat, intracerebral drug administration alone, genetically manipulated rats, and animals having any kind of experimental pathology. The reported results indicate that the effect of drugs on the inhibitory avoidance task performed in the elevated T-maze and on the spatio temporal indexes of anxiety measured in the X and plus mazes correlate with their effect in patients diagnosed with generalized anxiety disorder.
    [Show full text]
  • Potential Anxiogenic Effects of Cannabinoid CB1
    European Neuropsychopharmacology (2010) 20, 112–122 www.elsevier.com/locate/euroneuro Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: Comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142 K.S. Sink a, K.N. Segovia a, J. Sink a, P.A. Randall a, L.E. Collins a, M. Correa a,c, E.J. Markus a, V.K. Vemuri b, A. Makriyannis b, J.D. Salamone a,⁎ a Dept. of Psychology, University of Connecticut, Storrs, CT 06269-1020, USA b Center for Drug Discovery, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA c Dept. Psicologia, Area de Psicobiologica, University of Jaume I, Castello, Spain Received 11 September 2009; received in revised form 30 October 2009; accepted 10 November 2009 KEYWORDS Abstract Rimonabant; Anxiety; Cannabinoid CB1 inverse agonists suppress food-motivated behaviors, but may also induce Depression; psychiatric effects such as depression and anxiety. To evaluate behaviors potentially related to Cannabinoid; anxiety, the present experiments assessed the CB1 inverse agonist AM251 (2.0–8.0 mg/kg), the Aversive motivation; CB1 antagonist AM4113 (3.0–12.0 mg/kg), and the benzodiazepine inverse agonist FG-7142 Open field; (10.0–20.0 mg/kg), using the open field test and the elevated plus maze. Although all three Plus maze drugs affected open field behavior, these effects were largely due to actions on locomotion. In the elevated plus maze, FG-7142 and AM251 both produced anxiogenic effects. FG-7142 and AM251 also significantly increased c-Fos activity in the amygdala and nucleus accumbens shell. In contrast, AM4113 failed to affect performance in the plus maze, and did not induce c-Fos immunoreactivity.
    [Show full text]
  • Anxiety Disorders
    June 2017 Effects of Marijuana on Mental Health: Anxiety Disorders Susan A. Stoner, PhD, Research Consultant Highlights Many people report using marijuana to cope with anxiety, especially those with social anxiety disorder. Considering THC Locked appears vs. Unlocked to decrease Treatment anxiety Facilities at lower doses and increase anxiety at higher doses. CBD appears to decrease anxiety at all doses that have been tested. There are individual differences in responses to marijuana that are affected by a variety of factors, though tolerance develops over a short period of time with regular use. Using marijuana to cope with anxiety may offer some short-term benefit, but well-controlled studies indicate that use of marijuana is associated with increased likelihood of substance use disorders. Introduction Marijuana is the most commonly used drug of abuse in the United States.1 As found in the 2015 National Survey on Drug Use and Health, 22.2 million people aged 12 and older had used marijuana in the past month.1 Research suggests that marijuana use has increased over the past decade2-4 as perceptions of risk of harm from using marijuana among adults in the general population have steadily declined.4 As of June 2017, 26 states and the District of Columbia have enacted laws that have legalized marijuana use in some form, and 3 additional states have recently passed measures permitting use of medical marijuana.5 Mental health conditions figure prominently among the reasons given for medical marijuana use6, yet there is a dearth of rigorous, experimentally controlled studies examining the effects of marijuana on mental health conditions.7 This research brief will summarize what is known about the effects of marijuana on anxiety disorders.
    [Show full text]